1. Home
  2. PLAB vs NVCR Comparison

PLAB vs NVCR Comparison

Compare PLAB & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLAB
  • NVCR
  • Stock Information
  • Founded
  • PLAB 1969
  • NVCR 2000
  • Country
  • PLAB United States
  • NVCR Switzerland
  • Employees
  • PLAB N/A
  • NVCR N/A
  • Industry
  • PLAB Semiconductors
  • NVCR Medical/Dental Instruments
  • Sector
  • PLAB Technology
  • NVCR Health Care
  • Exchange
  • PLAB Nasdaq
  • NVCR Nasdaq
  • Market Cap
  • PLAB 1.2B
  • NVCR 1.4B
  • IPO Year
  • PLAB 1987
  • NVCR 2015
  • Fundamental
  • Price
  • PLAB $22.81
  • NVCR $12.72
  • Analyst Decision
  • PLAB Strong Buy
  • NVCR Buy
  • Analyst Count
  • PLAB 2
  • NVCR 7
  • Target Price
  • PLAB $31.00
  • NVCR $28.79
  • AVG Volume (30 Days)
  • PLAB 705.9K
  • NVCR 1.3M
  • Earning Date
  • PLAB 08-27-2025
  • NVCR 10-29-2025
  • Dividend Yield
  • PLAB N/A
  • NVCR N/A
  • EPS Growth
  • PLAB N/A
  • NVCR N/A
  • EPS
  • PLAB 1.77
  • NVCR N/A
  • Revenue
  • PLAB $856,152,000.00
  • NVCR $630,160,000.00
  • Revenue This Year
  • PLAB N/A
  • NVCR $6.68
  • Revenue Next Year
  • PLAB $5.06
  • NVCR $7.01
  • P/E Ratio
  • PLAB $12.85
  • NVCR N/A
  • Revenue Growth
  • PLAB N/A
  • NVCR 14.58
  • 52 Week Low
  • PLAB $16.46
  • NVCR $10.87
  • 52 Week High
  • PLAB $31.60
  • NVCR $34.13
  • Technical
  • Relative Strength Index (RSI)
  • PLAB 58.45
  • NVCR 53.05
  • Support Level
  • PLAB $21.86
  • NVCR $11.98
  • Resistance Level
  • PLAB $22.87
  • NVCR $12.83
  • Average True Range (ATR)
  • PLAB 0.77
  • NVCR 0.56
  • MACD
  • PLAB -0.05
  • NVCR 0.16
  • Stochastic Oscillator
  • PLAB 38.81
  • NVCR 53.43

About PLAB Photronics Inc.

Photronics Inc is a U.S.-based company that is principally engaged in manufacturing photomasks. The photomasks are photographic quartz or glass plates that contain microscopic images of electronic circuits that are used as a component in the manufacture of integrated circuits and flat-panel displays. The revenue from products designed for integrated circuits production accounts for the majority of total revenue, with the rest derived from products for flat-panel display production. The company's assets are located in Taiwan, Korea, and the United States. It generates revenue world-wide, including in the United States, Europe, Taiwan, Korea, China, and elsewhere in Asia, with Taiwan contributing the majority of total revenue.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: